EMEA-001185-PIP01-11-M08
Key facts
Invented name |
Rxulti
|
Active substance |
brexpiprazole
|
Therapeutic area |
Psychiatry
|
Decision number |
P/0294/2022
|
PIP number |
EMEA-001185-PIP01-11-M08
|
Pharmaceutical form(s) |
Film-coated tablet
|
Condition(s) / indication(s) |
Treatment of schizophrenia
|
Route(s) of administration |
Oral use
|
Contact for public enquiries |
Otsuka Pharmaceutical Development and Commercialisation Europe GmbH
E-mail: paediatric-info@otsuka-europe.com |
Decision type |
PM: decision on the application for modification of an agreed PIP
|